Serial CT scan images from patient with a partial response.

Slides:



Advertisements
Similar presentations
Yasir Rudha, MD; Amr Aref, MD; Paul Chuba, MD; Kevin O’Brien, MD
Advertisements

What is TNM? TNM is a system for classifying malignant tumours ! It is a cancer staging system, which describes the extent of a person's cancer ! Most.
Resection For Lung Metastases M62 Coloproctology Course.
PET in Colorectal Cancer. Indications for FDG PET Rising marker, (-) CT/MRI Nonspecific findings on CT/MRI, recurrence or post treatment changes? Known.
Potentially curative re-resection of recurrent CRC  Suture line recurrences  Isolated liver metastases  Isolated pulmonary metastases.
Treatment Options for Renal Cell Carcinoma By: Anthony Jurayj.
Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical.
Stereotactic Ablative Body Radiotherapy for Non small cell lung cancer
PET Criteria for Response Assessment After Completion of Therapy for Aggressive NHL and HL Definition of a positive PET scan (Visual assessment is adequate,
Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports  Daniel K. Ebner, BS, Tadashi Kamada, MD, PhD,
Figure 2 Response after initial increase in total tumour burden
Clonal evolution of resistance to sequential ALK inhibitor therapy.
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
A 30 year old man with headaches, imbalance and aphasia
Proof-of-concept clinical studies validating AZD9291 as a mutant-selective EGFR kinase T790M inhibitor. Proof-of-concept clinical studies validating AZD9291.
Hiren J. Mehta, MD, Tan-Lucien Mohammed, MD, Michael A. Jantz, MD 
Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets Case Rep Oncol 2016;9:
Paraneoplastic Opsoclonus-Myoclonus Syndrome as a New and Single Manifestation of Relapsing Disease in a Patient with Small Cell Lung Cancer  Ernest Nadal,
A, baseline and 4-week PET scan from patient 2 (MET c
Nat. Rev. Urol. doi: /nrurol
Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma  Sergio Bracarda, Alain Ravaud, Marino.
Otolaryngology referred this patient for imaging after palpating a mass in the “left parotid tail.” Axial contrast-enhanced CT scan through the mass reveals.
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.
Example of pretreatment (A and B) and 8-week posttreatment (C and D) PET CT images. Example of pretreatment (A and B) and 8-week posttreatment (C and D)
Clinical responses in patients.
Impact of immunosuppressive therapy on pulmonary function, recurrence of diffuse alveolar haemorrhage (DAH) and chest computed tomography (CT) findings.
Tumor sites and treatment timelines.
Treatment and diagnosis history, and response to targeted therapy, of a patient with pancreatic adenocarcinoma with an EGFR exon19 deletion. Treatment.
Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.
A 62-year-old man with subacute cognitive impairment and seizures.
A, Contrast-enhanced CT scans obtained with protocol C, B, and A (from left to right) in different patients with papillary thyroid cancer. A, Contrast-enhanced.
CT (left of images) showing calcified areas and PET (right of images) scans showing increased FDG-PET metabolic activity in the mediastinal mass (A) and.
Clinical response to anti-ERBB3 mAb therapy in a patient with an advanced NRG1-rearranged non–small cell lung cancer. Clinical response to anti-ERBB3 mAb.
Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.
Figure 1 The spread of colorectal cancer metastases
IL6 mRNA is not detected in metastatic prostate cancer cells.
A and B, CT images on a patient status post total thyroidectomy for thyroid cancer show a small enhancing lesion near the right tracheoesophageal groove.
History: 71 yo male post radical prostatectomy 4 years ago for Gleason 4+5 prostate cancer Pre-op staging CT and MDP bone scan were negative for metastatic.
Positive correlations between disease course and treatment-induced immune responses. Positive correlations between disease course and treatment-induced.
Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.
The treatment history and genomic landscape of a metastatic carcinoma with an extreme outlier response to combination therapy. The treatment history and.
Serial imaging before and after immunotherapy among patients with MDM2/4 amplifications (N = 6). Serial imaging before and after immunotherapy among patients.
Imaging studies in patients attaining objective response on phase I study. Imaging studies in patients attaining objective response on phase I study. A,
Serial chest CT scans of 33-year-old male with lung adenocarcinoma harboring EGFR-KDD documenting response to afatinib and subsequent acquired resistance.
Heterogeneous effects of fulvestrant were observed between lesions within individuals. Heterogeneous effects of fulvestrant were observed between lesions.
Antitumor activity. Antitumor activity. A, maximum change in target lesion size from baseline assessed according to RECIST 1.0 (n = 26). Six patients had.
Waterfall plot showing the relative change in median tumor FES uptake (SUVcor) in individual patients at the second scan compared with baseline. Waterfall.
A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.
Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.
Molecular heterogeneity can drive mixed response and treatment failure in EGC. A, PET images from Patient #4 obtained before treatment and upon disease.
Change in FES uptake in the tumor during fulvestrant treatment.
A) Chest CT showing a lobulated necrotic mass in left hilar region with foci of calcifications and spiculated ­margins at the time of diagnosis. b) PET-CT.
Frequent coamplification of RTKs in MET-amplified EGC
A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. A, pretreatment CT scan.
Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.
Model of minimal residual disease.
Genomic determinants of response to cytotoxic chemotherapy.
Rapid autopsy reveals interlesional and intralesional heterogeneity of resistance. Rapid autopsy reveals interlesional and intralesional heterogeneity.
Survival, subsequent therapies, and response.
Detection of E-cadherin fragments in human prostate cancer metastases.
Response to crizotinib in an 8-year-old boy with refractory IMT harboring a TFG–ROS1 fusion. Response to crizotinib in an 8-year-old boy with refractory.
Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor cells after weekly CAR+ T-cell treatment for 4 wks. Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor.
BRAF in-frame deletion confers response to MAPK inhibition.
Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.
BV6 increases bone metastasis.
In vivo shRNA screening strategy.
Single-site disease progression after 9 months of response to therapy in the right hemipelvis visualized by diffusion-weighted whole-body MRI. Top, fusion.
SCLC initiated from pulmonary neuroendocrine cells metastasizes without upregulating NFIB. A and B, Mouse models of SCLC. Rb1flox/flox;Trp53flox/flox;p130flox/flox;R26mTmG.
Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.
Papillary thyroid cancer.
Presentation transcript:

Serial CT scan images from patient with a partial response. Serial CT scan images from patient with a partial response. Scans demonstrate gradual resolution of sites of disease, including a lung mass, matted hilar lymph nodes, and one of the liver metastases. Although he was taken off study for treatment of an intercurrent small cell lung cancer, the patient remains alive and was without evidence of disease recurrence nearly 2 years after completion of this therapy. Red arrrows indicate areas of measurable disease. Rosalyn A. Juergens et al. Cancer Discovery 2011;1:598-607 ©2011 by American Association for Cancer Research